The announcement comes after company CFO told The Washington Post that medtech layoffs were, 'a failure of leadership'.
The German Federal Patent Court has ruled in favor of NanoString in a patent infringement case that has the company pitted against 10X Genomics.
This wildly popular new drug class is poised to disrupt several corners of the medical device world, including sleep apnea.